Volume 28, Number 3—March 2022
Research
Overseas Treatment of Latent Tuberculosis Infection in US–Bound Immigrants
Table 3
Reason | No. (%) participants |
---|---|
IGRA not processed for participants who consented to be tested | 162 (100) |
Previous TB or abnormality on chest radiograph | 119 (73) |
Hepatitis B | 25 (15) |
History of extrapulmonary TB | 3 (2) |
Previous treatment | 1 (1) |
Breastfeeding | 1 (1) |
Applying for visa type not included in study | 2 (1) |
Recent receipt of live virus vaccine | 1 (1) |
Unknown; may have withdrawn consent |
10 (7) |
3HP not offered to IGRA-positive participants | 32 (100) |
Hepatitis B | 18 (56) |
Hepatitis C | 5 (16) |
Previous TB or abnormality on chest radiograph | 1 (3) |
Liver disease | 1 (3) |
Planning to get pregnant in next 4 mo | 1 (3) |
Substance addiction | 1 (3) |
Previous LTBI treatment | 3 (9) |
Unknown | 2 (6) |
*IGRA, interferon-γ release assay; LTBI, latent tuberculosis infection; TB, tuberculosis; 3HP, 3-mo regimen of isoniazid and rifapentine.
Page created: December 13, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.